West Historical Income Statement

WST Stock

USD 331.40 0.00 0.00%

Historical analysis of West Pharmaceutical income statement accounts such as Depreciation And Amortization of 144.2 M, Total Revenue of 3.1 B, Gross Profit of 1.2 B or Other Operating Expenses of 2.4 B can show how well West Pharmaceutical Services performed in making a profits. Evaluating West Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of West Pharmaceutical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining West Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether West Pharmaceutical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About West Income Statement Analysis

West Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to West Pharmaceutical shareholders. The income statement also shows West investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

West Pharmaceutical Income Statement Chart

At this time, West Pharmaceutical's Total Operating Expenses is comparatively stable compared to the past year. Income Before Tax is likely to gain to about 732.9 M in 2024, despite the fact that Non Operating Income Net Other is likely to grow to (27.9 M).

Total Revenue Gross Profit Other Operating Expenses Operating Income Non Recurring

Total Revenue

Total revenue comprises all receipts West Pharmaceutical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of West Pharmaceutical Services minus its cost of goods sold. It is profit before West Pharmaceutical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of West Pharmaceutical. It is also known as West Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from West Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of West Pharmaceutical Services is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most accounts from West Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into West Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2021	2022	2023	2024 (projected)
Total Revenue	2.8B	2.9B	2.9B	3.1B
Depreciation And Amortization	122.3M	120.6M	137.3M	144.2M

Total Revenue Depreciation And Amortization

West Pharmaceutical income statement Correlations

	Depreciation And Amortization	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Expense	Selling General Administrative	Research Development	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.95	0.9	0.98	0.82	0.8	0.84	0.97	0.99	0.83	0.13	0.82	0.85	0.04	0.78	0.91	0.79	-0.37	0.73	0.25	0.6	0.75
Total Revenue	0.95		0.99	0.99	0.96	0.95	0.96	0.99	0.98	0.96	0.12	0.95	0.95	-0.11	0.77	0.96	0.94	-0.47	0.86	0.29	0.65	0.89
Gross Profit	0.9	0.99		0.97	0.99	0.98	0.99	0.97	0.95	0.99	0.12	0.98	0.95	-0.17	0.75	0.95	0.97	-0.47	0.89	0.3	0.64	0.92
Other Operating Expenses	0.98	0.99	0.97		0.92	0.9	0.93	1.0	0.99	0.92	0.13	0.91	0.92	-0.05	0.78	0.96	0.89	-0.45	0.82	0.28	0.64	0.85
Operating Income	0.82	0.96	0.99	0.92		0.99	0.99	0.93	0.89	1.0	0.14	1.0	0.95	-0.24	0.71	0.93	0.99	-0.48	0.91	0.29	0.62	0.93
Ebit	0.8	0.95	0.98	0.9	0.99		1.0	0.91	0.87	0.99	0.12	0.99	0.96	-0.27	0.69	0.92	0.99	-0.49	0.92	0.31	0.63	0.92
Ebitda	0.84	0.96	0.99	0.93	0.99	1.0		0.93	0.9	0.99	0.13	0.99	0.96	-0.24	0.71	0.94	0.99	-0.48	0.91	0.3	0.64	0.92
Cost Of Revenue	0.97	0.99	0.97	1.0	0.93	0.91	0.93		0.99	0.93	0.13	0.92	0.93	-0.06	0.78	0.96	0.9	-0.46	0.83	0.28	0.65	0.85
Total Operating Expenses	0.99	0.98	0.95	0.99	0.89	0.87	0.9	0.99		0.89	0.14	0.88	0.9	0.01	0.79	0.94	0.86	-0.41	0.78	0.3	0.63	0.82
Income Before Tax	0.83	0.96	0.99	0.92	1.0	0.99	0.99	0.93	0.89		0.19	1.0	0.95	-0.27	0.69	0.94	1.0	-0.48	0.91	0.33	0.66	0.95
Total Other Income Expense Net	0.13	0.12	0.12	0.13	0.14	0.12	0.13	0.13	0.14	0.19		0.18	0.22	-0.19	-0.13	0.26	0.2	-0.08	0.11	0.49	0.49	0.3
Net Income	0.82	0.95	0.98	0.91	1.0	0.99	0.99	0.92	0.88	1.0	0.18		0.94	-0.26	0.69	0.92	1.0	-0.46	0.9	0.33	0.64	0.95
Income Tax Expense	0.85	0.95	0.95	0.92	0.95	0.96	0.96	0.93	0.9	0.95	0.22	0.94		-0.26	0.66	0.95	0.93	-0.53	0.93	0.3	0.69	0.88
Interest Expense	0.04	-0.11	-0.17	-0.05	-0.24	-0.27	-0.24	-0.06	0.01	-0.27	-0.19	-0.26	-0.26		0.06	-0.13	-0.29	-0.03	-0.37	0.18	-0.14	-0.25
Selling General Administrative	0.78	0.77	0.75	0.78	0.71	0.69	0.71	0.78	0.79	0.69	-0.13	0.69	0.66	0.06		0.64	0.65	-0.07	0.73	-0.14	0.17	0.62
Research Development	0.91	0.96	0.95	0.96	0.93	0.92	0.94	0.96	0.94	0.94	0.26	0.92	0.95	-0.13	0.64		0.92	-0.62	0.83	0.48	0.81	0.91
Net Income From Continuing Ops	0.79	0.94	0.97	0.89	0.99	0.99	0.99	0.9	0.86	1.0	0.2	1.0	0.93	-0.29	0.65	0.92		-0.48	0.89	0.36	0.67	0.96
Non Operating Income Net Other	-0.37	-0.47	-0.47	-0.45	-0.48	-0.49	-0.48	-0.46	-0.41	-0.48	-0.08	-0.46	-0.53	-0.03	-0.07	-0.62	-0.48		-0.43	-0.64	-0.79	-0.59
Tax Provision	0.73	0.86	0.89	0.82	0.91	0.92	0.91	0.83	0.78	0.91	0.11	0.9	0.93	-0.37	0.73	0.83	0.89	-0.43		0.12	0.55	0.87
Interest Income	0.25	0.29	0.3	0.28	0.29	0.31	0.3	0.28	0.3	0.33	0.49	0.33	0.3	0.18	-0.14	0.48	0.36	-0.64	0.12		0.81	0.5
Net Interest Income	0.6	0.65	0.64	0.64	0.62	0.63	0.64	0.65	0.63	0.66	0.49	0.64	0.69	-0.14	0.17	0.81	0.67	-0.79	0.55	0.81		0.78
Reconciled Depreciation	0.75	0.89	0.92	0.85	0.93	0.92	0.92	0.85	0.82	0.95	0.3	0.95	0.88	-0.25	0.62	0.91	0.96	-0.59	0.87	0.5	0.78

Click cells to compare fundamentals

West Pharmaceutical Account Relationship Matchups

West Pharmaceutical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	103.3M	109.1M	122.3M	120.6M	137.3M	144.2M
Total Revenue	1.8B	2.1B	2.8B	2.9B	2.9B	3.1B
Gross Profit	605.7M	767.8M	1.2B	1.1B	1.1B	1.2B
Other Operating Expenses	1.5B	1.7B	2.1B	2.2B	2.3B	2.4B
Operating Income	296.6M	406.9M	752.3M	734M	676M	709.8M
Ebit	296.6M	422.6M	772.9M	767.3M	706.8M	742.1M
Ebitda	399.9M	531.7M	895.2M	887.9M	844.1M	886.3M
Cost Of Revenue	1.2B	1.4B	1.7B	1.8B	1.8B	1.9B
Total Operating Expenses	311.6M	360.9M	423.5M	402.2M	454M	476.7M
Income Before Tax	291.8M	401.3M	748.9M	679.9M	698M	732.9M
Total Other Income Expense Net	(4.8M)	(5.6M)	(3.4M)	(54.1M)	22M	23.1M
Net Income	241.7M	346.2M	661.8M	585.9M	593.4M	623.1M
Income Tax Expense	59M	72.5M	107.2M	114.7M	122.3M	128.4M
Interest Expense	4.7M	6.8M	7.2M	7.9M	9M	6.5M
Selling General Administrative	272.7M	302M	362.8M	343.7M	353.4M	194.7M
Research Development	38.9M	46.9M	52.8M	58.5M	68.4M	71.8M
Net Income Applicable To Common Shares	232.8M	346.2M	661.8M	585.9M	673.8M	707.5M
Net Income From Continuing Ops	232.8M	328.8M	641.7M	565.2M	593.4M	623.1M
Non Operating Income Net Other	12.6M	20M	24.9M	(25.5M)	(29.3M)	(27.9M)
Tax Provision	59M	72.5M	107.2M	114.7M	122.3M	83.0M
Interest Income	3.8M	6.8M	7.2M	2.8M	28M	29.4M
Extraordinary Items	(81.9M)	2.5M	1.4M	5.7M	6.6M	6.9M
Net Interest Income	(4.7M)	(6.8M)	(7.2M)	(2.8M)	19M	20.0M
Reconciled Depreciation	103.4M	109.1M	122.3M	120.6M	137.3M	124.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for West Stock Analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

West Historical Income Statement

About West Income Statement Analysis

West Pharmaceutical Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Operating Income

West Pharmaceutical income statement Correlations

West Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

West Pharmaceutical income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for West Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Net Income From Continuing Ops	+ 1.0	Income Before Tax

Net Interest Income	- 0.79	Non Operating Income Net Other
Interest Income	- 0.64	Non Operating Income Net Other
Non Operating Income Net Other	- 0.62	Research Development
Reconciled Depreciation	- 0.59	Non Operating Income Net Other
Non Operating Income Net Other	- 0.53	Income Tax Expense
Non Operating Income Net Other	- 0.49	Ebit